Anteris Technologies Global Corp. (AVR) · Sep 23, 2026 · Material agreement

Anteris extends Harvey supply deal, but only through a short-term bridge

4-month supply extension — Supply continued for four months after May 24, 2026

Anteris preserves a key supply relationship for DurAVR, yet the four-month extension mostly confirms an already disclosed contingency—not a new strategic win.

Anteris is still a development-stage structural-heart company building the DurAVR transcatheter heart valve toward commercialization, with manufacturing capacity being expanded to support the PARADIGM clinical program. The filing preserves continuity, not momentum: Harvey agreed to keep supplying Anteris for four additional months after the agreement’s initial term ended on May 24, 2026. 〔0〕 That avoids an immediate interruption to a supplier relationship tied to the company’s product-development and manufacturing effort, but it does not establish a durable long-term arrangement or add new economics.

Most of the news was already known: Anteris had previously disclosed that the Harvey agreement expired in May 2026 and that Harvey would continue supplying for four months if the agreement was not extended. The 8-K therefore formalizes the expected contingency almost at the end of that bridge period rather than changing the company’s commercial or clinical trajectory.

Bottom line: This is operationally useful but strategically routine: DurAVR’s supply line remains intact, while the filing leaves the longer-term supply question unresolved and adds little beyond prior disclosure. 〔1〕

Original filing on SEC EDGAR

More Anteris Technologies Global Corp. news

Anteris extends Harvey supply deal, but only through a short-term bridge | AVR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.